Data from VAYHIT3 presented at ASH 2025 suggest efficacy and safety of ianalumab in patients with primary immune thrombocytopenia.
Philip Choi, MBBS, PhD
Advertisement
Articles by Philip Choi, MBBS, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5